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Introduction: The historical development, frequency, and impact of frontotemporal
dementia (FTD) are less clear in Latin America than in high-income countries. Although
there is a growing number of dementia studies in Latin America, little is known collectively
about FTD prevalence studies by country, clinical heterogeneity, risk factors, and genetics
in Latin American countries.
Methods: A systematic review was completed, aimed at identifying the frequency,
clinical heterogeneity, and genetics studies of FTD in Latin American populations.
The search strategies used a combination of standardized terms for FTD and
related disorders. In addition, at least one author per Latin American country
summarized the available literature. Collaborative or regional studies were reviewed
during consensus meetings.
Results: The first FTD reports published in Latin America were mostly case reports.
The last two decades marked a substantial increase in the number of FTD research in
Latin American countries. Brazil (165), Argentina (84), Colombia (26), and Chile (23) are
the countries with the larger numbers of FTD published studies. Most of the research
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has focused on clinical and neuropsychological features (n = 247), including the local
adaptation of neuropsychological and behavioral assessment batteries. However, there
are little to no large studies on prevalence (n = 4), biomarkers (n = 9), or neuropathology
(n = 3) of FTD.
Conclusions: Future FTD studies will be required in Latin America, albeit with a greater
emphasis on clinical diagnosis, genetics, biomarkers, and neuropathological studies.
Regional and country-level efforts should seek better estimations of the prevalence,
incidence, and economic impact of FTD syndromes.
Keywords: frontotemporal dementia, Latin America, history, prevalence, genetics, biomarkers
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a
neuropathological designation used to identify a group of
neurodegenerative diseases of the frontal and anterior temporal
lobes, typically associated with specific pathologies (1). In
most cases, FTLD features pathological inclusions of either the
microtubule-associated protein tau (MAPT) or the transactive
response DNA-binding protein of 43 kDa (TDP-43), named
FTLD-tau and FTLD-TDP, respectively (2). TDP-43 is the major
pathological protein deposited in FTLD and amyotrophic lateral
sclerosis (ALS) (3–5). FTLD can be sporadic or hereditary, the
latter most commonly due to mutations in several genes, such as
MAPT, progranulin (GRN), TARDBP, or chromosome 9 open
reading frame 72 (C9orf72) expansion.
The core clinical syndromes associated with FTLD are
behavioral or language symptoms and are generally called
frontotemporal dementia (FTD). There are three main clinical
variants distinguished by early and predominant symptoms:
behavior variant frontotemporal dementia (bvFTD); semantic
variant primary progressive aphasia (svPPA); and non-fluent
variant primary progressive aphasia (nfvPPA) (6) bvFTD
accounts for roughly 60% of FTD cases, and the other 40% are
language variants of FTD (7). Related FTD disorders include
frontotemporal dementia with motor neuron disease (FTD-
MND), progressive supranuclear palsy syndrome (PSP-S), and
corticobasal syndrome (CBS).
FTD is the second most common dementia disorder in
individuals under the age of 65 years old and accounts for 5–10%
of dementia patients older than 65 years (3, 4). In the US, the total
number of cases with FTD syndromes range from 15 to 22 per
100,000 people in the US (8, 9) with ∼20,000 to 30,000 persons
living with FTD (9). The incidence of FTD is estimated to be 1.61
to 4.1 cases per 100,000 people annually (8, 9).
FTD is likely underdiagnosed due to the relatively low
recognition within the medical community, little disease
awareness in the population, and the overlap with a multitude
of psychiatric disorders (10–13). Therefore, prevalence studies
on bvFTD and the other FTD syndromes are challenging
because many cases are misclassified, as the disease is largely
unrecognized (7, 9).
The frequency and correlates of the impact of FTD are
less clear in Latin American countries. Although there is a
growing number of dementia studies in Latin America, little is
known collectively about FTD studies by country, its clinical
heterogeneity, risk factors, and genetics in Latin American
countries. Therefore, we aimed to systematically review FTD
studies reported in Latin America. This systematic review offers
an overview of the history and evolution of FTD in Latin
America and reports on FTD prevalence and clinical and
neuropsychological syndromes. This is followed by a review
of the biomarkers, neuropathology, and genetic studies in
the region.
METHODS
A systematic review was completed at identifying and describing
the frequency, clinical heterogeneity, and research studies on
FTDs in Latin American populations. The search strategy
was developed with assistance from a research committee
formed by a medical librarian, representatives from multiple
Latin American countries (local dementia experts and clinical
researchers), and other stakeholders with expertise in FTD.
The research committee provided feedback and guidance on
the proposed search strategies, selection criteria, and data
analysis approach.
The published literature was searched using strategies
designed by a medical librarian for the concepts of FTD, Latin
American countries, and related synonyms. These strategies were
created using a combination of controlled vocabulary terms
and keywords and were executed in Medline (Ovid) 1946-,
Embase.com 1947-, Scopus 1823-, PsycInfo, Cochrane Library
(including CENTRAL), LILACS 1982-, and SciElo.org. No filters
or limits were applied to the search. All searches were completed
on September 14, 2020. Full search strategies are provided in the
Supplementary Material. A total of 483 results were retrieved
from the literature search and imported into Endnote. Dementia
experts and clinical researchers from Latin America (at least
one per country) were asked to provide information on FTD
publications in the Latin American region, yielding 213 records
through hand-searching. A total of 696 citations retrieved by
these methods (literature search + dementia experts reports)
were compiled and screened for duplicates. Duplicate citations
(n = 272) were accurately identified and removed for a total of
424 unique citations.
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After removing duplicates all citations (n = 424) were
screened for appropriateness against the inclusion and exclusion
criteria. Studies were included if they reported on (1) clinical
features of FTD and (2) reports from populations living in
Latin American countries. Reports describing non-FTD studies
were excluded from this study. Studies published by Latin
American authors but that did not include Latin American
participants, as well as studies of Hispanics not living in Latin
American countries, were also excluded. Studies that were done
in collaboration (regional or international) were included if
they involved Latin American participants. Poster presentations
and meetings abstracts were excluded, except in areas where its
relevance was sought to contribute to the understanding of FTD
in Latin America (e.g., genetics and prevalence studies). After the
abstract screening phase, studies that met the inclusion criteria
(n = 398) underwent full-text assessment for eligibility (second
screening stage) and were selected based on their relevance.
Three hundred and twenty-two (322) peer-reviewed publications
were selected for the final analysis (Figure 1).
At least one author per Latin American country summarized
the FTD literature that was found in their country; collaborative
or regional studies were reviewed during consensus meetings.
From each research study, information on sociodemographic
characteristics, country report, and genetics were extracted.
Information on clinical features (age at onset, age of death,
disease duration, clinical presentation, atypical manifestations,
and neurological findings) were obtained when available.
We considered each symptom or sign as present or absent
when clearly stated in the reports. A group composed
of three of the authors (MIB, JL, and RN) received all
the comments and classified the FTD reports from Latin
American countries according to publication date (before 2000
or after 2000), epidemiology, clinical presentation, genetics,
and neuropathology.
This study was reported according to the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA)
guidelines (14).
RESULTS
A total of 322 peer-reviewed publications were included in
the final review and analysis. Twenty-two peer-reviewed papers
were published during the twentieth century and provide an
overview of the history and early development of the FTD field
in Latin America. The early 2000s marked an increase in the
research related to FTD, with a spike between 2010 and 2015
(Figure 2). Brazil (165), Argentina (84), Colombia (26), and
FIGURE 1 | Diagram of the study selection process for the systematic review.
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Chile (23) are the countries with the larger number of published
reports (Table 1). Most of the research has focused on clinical
and neuropsychological features (n = 247), including the local
adaptation of neuropsychological and behavioral assessment
batteries. However, there are little to no large studies on
prevalence (n = 4), biomarkers (n = 9), or genetics (n = 36) of
FTD (Figure 3).
Evolution of FTD in Latin America
(Twentieth Century)
The first Latin America publication of bvFTD associated with
ALS was reported by Tretiakoff and Amorim in 1924 (15).
The case report described a young woman with absolute
indifference, complete absence of affective feelings, and severe
impairment of memory, which were followed by motor neuron
signs of ALS. The neuropathological examination of the case
described evidence of ALS but no signs of other dementia-
causing pathology in the brain. The authors hypothesized
that dementia was part of ALS and recommended the search
for signs of involvement of motor neurons in dementia
cases, a practice currently accepted in the clinical workup of
FTD cases.
In 1987, Nitrini et al. described three patients with
progressive supranuclear palsy (PSP) in Brazil who presented
with elementary motor perseveration before the appearance of
any other distinctive features of the disease (16). The authors
suggested that motor perseveration was an important sign for
early diagnosis and a key element for the clinical characterization
of PSP.
FIGURE 2 | Frontotemporal dementia and related disorders publications in Latin America by years.
TABLE 1 | Frontotemporal dementia and related disorders publications in Latin American countries.
Country Clinical cognitive Genetics** Biomarkers Reviews by Latin America authors Total
bvFTD* FTD-ALS PPA CBS/PSPs
Brazil 74 8 33 2 25 5 15 165
Argentina 54 – 6 9 3 3 2 77
Colombia 16 – 5 – 1 1 3 26
Chile 11 1 3 3 1 – 4 23
Peru 8 1 1 1 – – – 11
Uruguay 2 – 1 – 1 – – 4
Mexico 2 – 1 – 2 – – 5
Cuba 1 – 1 – 2 – – 4
Venezuela 3 – – – – – 1 4
Ecuador – 1 – – – – – 1
Dominican republic – – – – 1 – – 1
Puerto rico – – – – 0 – – 0
Guadeloupe 1 – – – – – – 1
Total 172 11 51 15 36 9 25 322
FTD, frontotemporal dementia; bvFTD, behavioral variant FTD; ALS, amyotrophic lateral sclerosis CBS/PSPS, corticobasal syndrome/progressive supranuclear palsy syndrome; PPA,
primary progressive aphasia. *2 additional epidemiological abstracts are discussed but not included in this table. **17 additional abstracts are discussed but not included in this table
(eight from Brazil, five from Argentina, one from Colombia, one from Cuba, one from the Dominican Republic, and one from Puerto Rico). There are 22 regional collaborative studies
(nine between Argentina, Chile, and Colombia; seven between Argentina and Colombia; two between Argentina and Chile; two between Argentina and Perú; one between Brazil and
Chile; and one between Cuba, Uruguay, and Ireland. Collaborative studies were assigned to the country of the first author or to the nationality of the patients included.
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FIGURE 3 | Frontotemporal dementia and related disorders research in Latin America by country and topics. Panel (A) describe percentage of frontotemporal
dementia studies in Latin America by research area. Panel (B), describe the number of FTD publications by country.
In 1989, Oliveira et al. reported a patient with difficulties
in comprehension of written texts that were followed by other
language disturbances and dementia (17).
In 1992, Trevisol-Bittencourt, also from Brazil, reported a case
of PSP with dementia and highlighted diagnostics challenges due
to the presence of both “subcortical dementia” and frontal lobe
syndrome (18).
In 1994, Donoso et al., from Chile, reported six cases
of degenerative dementia with frontal or frontotemporal
hypoperfusion on SPECT (19). Five cases were classified
as “frontal progressive dementia,” whereas one patient had
progressive aphasia. In the same year, Leiguarda et al., from
Argentina, in collaboration with the Institute of Neurology of
the University College of London, published a description on
apraxia and corticobasal degeneration, followed by a relevant
contribution to the knowledge of apraxia (20–23).
Several case descriptions populated the regional literature
from 1995 to the 2000s.
In a publication on the diagnosis of 100 patients evaluated in
an outpatient memory clinic in Brazil, Nitrini et al. (24), reported
two cases classified as frontal lobe dementia. In Delgado et al.
(25) from Brazil, reported a non-fluent PPA with MRI revealing
atrophy on the left perisylvian fissure region. In 1998, three
patients with neuropathologically confirmed FTD with motor
neuron disease whomanifested hallucinations were reported, and
a hypothesis about the occurrence of hallucination in dementia
associated with MND was proposed by Nitrini and Rosemberg
(26). Caixeta and Nitrini described the clinical features of
10 Brazilian patients with FTD, searching for qualitative and
quantitative behavioral changes. Disinhibition predominated
in six patients, apathy in four, while all patients manifested
repetitive behaviors (27).
In 1998 Allegri et al. (28) compared the cognitive profile
of 12 Argentinian patients with bvFTD and 20 patients
with probable Alzheimer’s disease, showing that FTD patients
scored significantly better than AD patients in memory tests,
calculations, visuospatial abilities, and the naming test. AD
patients performed better on executive tasks.
A clinical and pathological report of a case of FTD associated
with ALS was published by De Brito-Marques and DeMello (29),
describing neuropathological findings similar to those described
by Gustafson (30). In Doval and Gaviria (31), from Venezuela,
published a review on FTD emphasizing their opinion that FTD
was not a new clinical entity but a redefinition of the classical
Pick’s disease, an opinion that reflected the central concept on
dementia diagnosis during most of the twentieth century in Latin
America and most of the Western countries (32, 33).
Finally, a Chilean and an Uruguayan investigator participated
in the development of the Frontal Assessment Battery (FAB)
test (34). After these early papers, the number of scientific
publications increased exponentially (Figure 2).
Clinical Presentation and Neuropsychology
of FTD in Latin America
In the decade between 2000 and 2010, most of the publications
described clinical, neuropsychological features, and structural
imaging of FTD cases (Table 1). In addition, several authors have
raised concerns about the difficulties and under-diagnosis of FTD
and related disorders in Latin American countries (35–38).
FTD Prevalence Estimates in Latin America
There are few studies on the prevalence of FTD in Latin
American countries. In a systematic review, Custodio et al. (39)
described FTD prevalence in three Latin American countries
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[Venezuela (40), Perú (41), Brazil (42, 43)] ranging from 1.2 to 1.7
per 1,000. In a population-based study in an area of Maracaibo,
Venezuela, in subjects older than 54 years, the prevalence of all-
cause dementia was 8.04%, while the prevalence of FTD was
1.5% (44). There are also two studies presented at International
conferences: one population study from Mexico with 2003
participants estimated a prevalence of FTD of 0.9%, and another
5-year population study with nearly 3,000 participants from
Habana Cuba found a prevalence of FTD of 1.1% (45).
Other studies report the frequency of FTD within dementia
cohorts in memory clinics. One study in Brazil reported a 3.5%
frequency of FTD in 261 dementia cases assessed between 1989
and 1998, using the Brun criteria (46). Two studies fromMemory
clinics in Colombia report an FTD frequency between 11.5 and
12.9% (47, 48). Finally, one study in a memory clinic in Santiago,
Chile, found 57 FTD patients among 3,700 dementia patients
assessed between 1981 and 2008, using the Neary et al. (3) criteria
in a memory clinic in Santiago (1.5%) (49).
FTD Clinical and Neuropsychology Studies in Latin
America
The majority of the publications in Latin America (n = 247)
describe the clinical features of FTD. Brazil has the largest
number of publications on the clinical and neuropsychological
characteristics of FTD. Also, there are case reports of late-onset
(>85) bvFTD (50). It is also interesting to mention a paper
on long-term severe mental disorders preceding bvFTD in a
Brazilian cohort (51).
Argentina has several papers on the brain structural correlates
of executive and social cognition and also decision-making
cognition and moral judgment in bvFTD and PPA (52–67).
The relationship between FTD and creativity and theory of
mind has also been explored (68–70). Recent papers also report
the use of automated computational approaches and machine
learning to aid in the diagnosis of FTD (71, 72). Taragano
et al. (73–75) published several papers on mild behavioral
impairment and Tabernero et al. (76, 77) published papers on
facial emotion recognition.
There are several publications related to the validation of tests
in Spanish and Brazilian Portuguese (78–85). It is also important
to mention that a group at the Institute of Cognitive Neurology
(INECO) in Argentina developed the INECO Frontal Screening
(IFS) as a brief, sensitive, and specific tool to assess executive
functions in dementia (86). This test has also been validated in
Chile (83), Perú (87), and Brazil (88).
Finally, there are many publications of collaborative research
and between Latin-American and the US or European Countries.
It is interesting to note that there are also many joint publications
within the region, namely, Argentina–Perú (79, 87), Argentina–
Colombia–Chile (56, 66, 89, 90), Argentina–Chile (67), and
Argentina–Colombia (54, 63, 72).
Genetics of FTD in Latin America
The genetics of FTD syndromes in Latin America remains
understudied, with no FTD large genetic studies aimed at
identifying novel or functional rare variants in the region.
However, there are family reports from various countries,
including Brazil (91, 92), Argentina (93), Uruguay (94), Cuba
(95), Chile (96), and Caribbean origin families (97) (Figure 4).
Families carrying C9ORF72 have been described in Chile (96),
Cuba (95), Brazil (98, 99), and Argentina (100, 101), presenting
with a significant phenotypic heterogeneity (ALS vs. bvFTD
vs. bvFTD-MND). Families featuring GRN pathogenic variants
have been described in Brazil (91, 92), Uruguay (94), Argentina
(102), and the Caribbean (97). MAPT mutations have only been
reported in Brazilian (103), and Argentinian (104), families,
while TARDBP mutations have only been reported in Brazil.
A missense mutation (R93C) in the valosin-containing protein
(gene) was also described in a Brazilian family presenting
with progressive myopathy together with clinical and cognitive
features of FTD (105). The study of other genetic factors related
to FTD is also limited in Latin America (95, 106). Recent findings
by Nascimento et al. showed a higher frequency of TDP-43
pathology in cognitively healthy Asian Americans compared to
Caucasians living in Brazil (107); similarly, Hardiman et al. (95)
described a higher frequency of C9orf72 repeat expansions in an
Irish FTD-ALS cohort compared to a similar cohort in Cuba,
suggesting possible differences in FTD-related neuropathology
and neurodegeneration according to ethnicity. Future studies
should address whether observed differences are explained by
health and social disparities or possible ethnic-related protective
factors against clinical expression of TDP-43 proteinopathies.
FTD Biomarkers and Neuropathology in Latin
America
We found relatively few reports with extensive documentation
on neuropathology, biomarker profiles, and disease progression
in Latin American populations, making genotype–phenotype
correlations difficult in the region. Although the use of
dementia biomarkers is not widespread across Latin American
FIGURE 4 | Frontotemporal dementia and genetic in Latin America. C9orf72,
chromosome 9 open reading frame 72; MAPT, Microtubule-Associated Protein
Tau; GRN, Progranulin; TARDBP, 43-kDa transactive response
(TAR)-DNA-binding protein.
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countries, studies using biomarkers in FTD cohorts are
available in Argentina (108), Brazil (109), and Uruguay
(110). Neuroimaging studies in Latin American populations
mainly describe structural findings consistent with the atrophy
patterns reported in FTD studies from high-income countries.
Neuropathological reports were scarce and only available in
Brazilian cohorts (107, 111, 112).
Primary Progressive Aphasia
In our review, we found a relatively low number of PPA reports
in Latin America, with two reports before 2,000, 13 between 2000
and 2010, and 42 from 2011 to 2020. Similar to the findings in
bvFTD, Brazil has the greatest number of publications in Latin
America (36 vs. 63, respectively). There are PPA studies reported
in Argentina (n= 12), Chile (n= 1), Colombia (n= 4), Peru (n=
2), Cuba (n= 1), Mexico (n= 1), and three collaborative studies:
Argentina/Chile/Australia (n = 1), Argentina/Chile/Colombia,
and Australia (n = 2). Some of these manuscripts have already
been cited in the previous sections.
According to the available reports, the frequency of PPA
syndromes is low. Diagnostic classification also varies within
PPA cohorts and country reports. In a Chilean study by Donoso
et al. (49), 15.8% of the cases in an FTD cohort received a
PPA diagnosis. In a consecutive series of 100 Brazilian PPA
cases (113) using the classification proposed by Gorno-Tempini
et al. (114), 35 were diagnosed as svPPA, 29 as nfvPPA, 16 as
lvPPA, and 20 were considered unclassifiable. More recently,
Campanha et al. (115) described clinical characteristics of 19
featuring PPA syndrome; of those, 10 fulfilled criteria for svPPA,
five for nfvPPA, three for lvPPA, and one case was considered
unclassifiable. Other key features reported in the PPA have been
described in Brazilian and Argentinian cohorts. In 2016, Marin
et al. published a study of swallowing problems in 16 PPA patients
(116). Clinical presentations as “psychiatric disorders” have also
been reported (117).
Hosogi Senaha et al. (118) published the case study of a SD
patient without surface dyslexia, a sign usually found in most of
the SD cases to date. Similarly, in 2012, Wilson and Martínez-
Cuitiño (119) reported a Spanish-speaking SD case similar to the
Brazilian case. Both studies raise awareness about the possible
absence of surface dyslexia in Spanish and Portuguese speakers
presenting with SD, probably related to the relatively transparent
orthographies of both languages. It is worth noting that both
patients were able to read non-words, regular and irregular
words, and foreign words correctly but with difficulties in written
comprehension. In both studies, the authors associated patients’
performance—reading of irregular and foreign words without
meaning—with the use of the direct lexical reading process.
To the best of our knowledge, there are no large
neuropathology reports on PPA cohorts. Most of the
reports are based on case experiences. de Brito-Marques
et al. (2011) reported a nfvPPA longitudinal case study with
histopathologic analysis (120).
Strategies for languages rehabilitation in PPA has been
reported from single or multiple case studies in Brazil and
Mexico (121–124).
FTD and Motor Neuron Disease
Frontotemporal dementia and motor neuron disease (FTD-
MND) has been recognized as overlappingmultisystem disorders
(125). In this section, we focus our review on Latin American
studies describing the overlap between the two conditions.
Studies describing amyotrophic lateral sclerosis (ALS) cohorts
without assessments of cognitive measures were excluded from
this review. As mentioned above, reports of cases combining
the clinical picture of MND with mental symptoms, personality
change, or dementia in Latin America date back to 1924 (15).
Most of the reports on FTD/MND in Latin America are
case reports, including a wide range of cognitive presentations
combined with different MND syndromes, including ALS (29,
126–128) and primary lateral sclerosis (PLS) (129). There is a
relative lack of large studies describing the overlap between the
two conditions in Latin America, which might be related to
the scarcity of adequate cognitive screening methods suitable
for Spanish- and Portuguese-speaking populations with low
education. To the best of our knowledge, there are only two
cohorts studies exploring cognitive and behavioral presentations
overlapping with MND/ALS (130, 131).
Recent efforts in the region, especially in Brazil, are on the way
aimed to validate and implement adequate and more systematic
cognitive screening methods in Dementia/ALS cohorts. Branco
et al. (81) validated the Amyotrophic Lateral Sclerosis Cognitive
Behavioral Screen (ALS-CBS) in Brazil and this is now amiable
in Portuguese. A Spanish version (132) of this instrument and
education adjusted measures (133) are also available and can now
be used across the region.
DISCUSSION
The first publications of Latin American authors in the twentieth
century were mostly case reports or small series of patients
in which the clinical features were described. There were also
a few papers with deeper reasoning on apraxia in several
movement disorders and on frontal type of disinhibition in
PSP. In the last two decades, most of the papers report
on clinical and neuropsychological features of FTLD. Case
descriptions, translations, and adaptations of neuropsychological
and behavioral tests were the predominant publications by
Latin American authors. Argentina has contributed with several
interesting publications on social cognition and decision making.
Although there were only a few reports on FTD prevalence
in the region, the reported prevalence is relatively low compared
to North America and Europe. Nevertheless, future studies will
be needed to determine whether this is true or a reflection that
the disease is still underrecognized in Latin American counties.
Available data from surveys suggest that FLD is not recognized
by families and general physicians (35–38).
There are fewer studies published in Latin America related
to the language variants of FTLD in comparison to the
number of studies related to the bvFTD. Studies on PPA
have increased substantially during recent years and also
advanced from case reports to case series and, more recently,
to rehabilitation initiatives. However, more sensitive methods to
detect language variants are needed, especially as the classical
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testing methods used for English speakers cannot apply to
Spanish or Portuguese speakers.
Similarly, there is a relative lack of large studies describing
the overlap between FTD/MND in Latin America or exploring
the cognitive and behavioral manifestations in MND/ALS,
which may be related to the scarcity of adequate cognitive
screening methods suitable for Spanish- and Portuguese-
speaking populations with low education. Two instruments,
that provide adequate cognitive screening methods suitable
for Spanish and Portuguese-speaking populations with low
education, have been recently validated and are expected to
improve studies in this area.
Only a few neuropathological studies on FTLD have been
published, and all of them are from Brazil. The relatively low
number of neuropathology studies might be related to lack of
resources; brain donation protocols require the existence of brain
banks and trained personnel, which are scarce in the region.
Overall, most of the FTD studies are concentrated in a few
countries (Brazil, Argentina, Colombia, and Chile), with only
a few collaborative studies between Latin American countries
and between Latin American countries and more developed
centers in North America and Europe. Collaboration may
represent an alternative to achieve better results and more
robust studies in a region where research resources and funding
are scarce.
Genetics is another area where future studies will be required.
Much of the population of Latin American countries is a
mixture of native American, European, African, and some Asian
immigration. Therefore, it is expected to find similar mutations
to those already described in the literature. In addition, the
existence of novel mutations in the native American populations
and the effect of admixture in gene expression, disease onset, and
clinical heterogeneity should be further studied.
This systematic review also found several relevant conference
abstracts with large series of cases but, unfortunately, they did
not end up in peer-reviewed publications. This may be explained
by a lack of privileged time and grants to perform research
in Latin American countries, as well as difficulties in reaching
publications in a foreign language. Although there has been
improvement in the last few years, academic and governmental
institutions in Latin America should implement protected time
for their researchers aimed to facilitate research dissemination.
Public and private funds should be directed toward research
grants that will improve the research and consistency of reports
coming from Latin American researchers.
CONCLUSIONS
The analysis of the history of FTLD research in Latin America
shows that there are several gaps in knowledge that remain to
be explored and activities to be developed by the community.
Based on our findings, we believe research on epidemiology and
genetics of FTD in Latin America should be priorities. Several
studies show that general physicians, neurologists, psychiatrists,
and the lay public are unaware of these diseases. More
collaborative studies are needed, both between Latin American
countries and with developed centers in HIC, mainly on genetics
and biomarkers. The interchange of undergraduate, graduate,
and post-graduate students and academic professors between
research centers in Latin America with those in the developed
world has already started, and this is likely to change the history
of FTD in Latin America. The recent formation of the Latin
America network (RedLat) to study FTLD is tasked to increase
these collaborations.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/Supplementary Material, further inquiries can be
directed to the corresponding author/s.
AUTHOR CONTRIBUTIONS
JL-G, MB, and RN: study concept and design, acquisition,
analysis, interpretation of data, and drafting of the manuscript.
JL-G: project administration. RN: study supervision. All authors
critical revision of the manuscript for important intellectual
content, had full access to all the data in the study, and take
responsibility for the integrity of the data and the accuracy of the
data analysis.
FUNDING
MB has received funding from FONDECYT: 1190958, RN has
received funds from CNPq.
SUPPLEMENTARY MATERIAL




1. Rabinovici G, Miller B. Frontotemporal lobar degeneration: epidemiology,
pathophysiology, diagnosis and management. CNS Drugs. (2010) 24:375–
98. doi: 10.2165/11533100-000000000-00000
2. Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal
dementia: insights into disease mechanisms from postmortem studies. J
Neurochem. (2016) 138:54–70. doi: 10.1111/jnc.13588
3. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al.
Frontotemporal lobar degeneration: a consensus on clinical diagnostic
criteria. Neurology. (1998) 51:1546–54. doi: 10.1212/WNL.51.6.1546
4. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the
behavioural variant of frontotemporal dementia. Brain. (2011) 134:2456–
77. doi: 10.1093/brain/awr179
5. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A
KJ, Dobson-Stone C, et al. Frontotemporal dementia and its
subtypes: a genome-wide association study. Lancet Neurol. (2014)
13:686–99. doi: 10.1016/S1474-4422(14)70065-1
6. Lanata SC, Miller BL. The behavioural variant frontotemporal dementia
(bvFTD) syndrome in psychiatry. J Neurol Neurosurg Psychiatry.
(2016) 87:501–11. doi: 10.1136/jnnp-2015-310697
Frontiers in Neurology | www.frontiersin.org 8 September 2021 | Volume 12 | Article 710332
Llibre-Guerra et al. Frontotemporal Dementia in Latin America
7. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia.
Int Rev Psychiatry. (2013) 25:130–7. doi: 10.3109/09540261.2013.776523
8. Coyle-gilchrist ITS, Dick KM, Vázquez P, Wehmann E, Wilcox
A, Lansdall CJ, et al. Prevalence, characteristics, and survival of
frontotemporal lobar degeneration syndromes. Neurology. (2016)
86:1736–43. doi: 10.1212/WNL.0000000000002638
9. Knopman DS, Roberts RO. Estimating the number of persons with
frontotemporal lobar degeneration in the US population. J Mol Neurosci.
(2011) 45:330–5. doi: 10.1007/s12031-011-9538-y
10. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin katherine P.
The diagnostic challenge of psychiatric symptoms in neurodegenerative
disease: rates of and risk factors for prior psychiatric diagnosis in patients
with early neurodegenerative disease. J Clin Psychiatry. (2011) 72:126–
33. doi: 10.4088/JCP.10m06382oli
11. Velakoulis D, Walterfang M, Mocellin R, Pantelis C, McLean C.
Frontotemporal dementia presenting as schizophrenia-like psychosis in
young people: Clinicopathological series and review of cases. Br J Psychiatry.
(2009) 194:298–305. doi: 10.1192/bjp.bp.108.057034
12. Gálvez-Andres A, Blasco-Fontecilla H, Gonza’lez-Parra S, Molina J de
D, Padín JM, Rodriguez RH. Secondary bipolar disorder and diogenes
syndrome in frontotemporal dementia. J Clin Psychopharmacol. (2007)
27:722–3. doi: 10.1097/JCP.0b013e31815a57c1
13. Miller B, Llibre Guerra JJ. Frontotemporal dementia. In: Handbook of
Clinical Neurology. Oxford: Elsevier B.V. (2019). p. 33–45.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ. (2009)
339:332–6. doi: 10.1136/bmj.b2535
15. Andrade LA, Selikhova M, Lees AJ. Konstantin N. Tretiakoff in
Brazil: a historical perspective and discussion of his contribution
to brazilian neuroscience. Arq Neuropsiquiatr. (2009) 67:322–7.
doi: 10.1590/s0004-282x2009000200032
16. Nitrini R. Elementary motor perseveration in early diagnosis
of progressive supranuclear palsy. Arq Neuropsiquiatr. (1987)
45:29–32. doi: 10.1590/S0004-282X1987000100004
17. De Oliveira SA, Castro MJ, Bittencourt PR. Slowly progressive aphasia
followed by Alzheimer’s dementia: a case report. Arq Neuropsiquiatr.
(1989) 47:72–5.
18. Trevisol-Bittencourt PC. Progressive supranuclear palsy (Steele-Richardson-
Olszewski syndrome): report of a case and review of the literature.
Arq Neuropsiquiatr. (1992) 50:369–74. doi: 10.1590/S0004-282X199200030
0018
19. Prefrontal Dementias: Clinical Features and SPECT in 6 Cases Demencias
Prefrontales: Clínica y SPECT en Seis Casos. Available online at: http://
repositorio.uchile.cl/handle/2250/162553 (accessed March 28, 2021).
20. Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD. The nature of
apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry. (1994)
57:455–9. doi: 10.1136/jnnp.57.4.455
21. Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden
CD. Apraxia in Parkinson’s disease, progressive supranuclear palsy,
multiple system atrophy and neuroleptic-induced parkinsonism. Brain.
(1997) 120:75–90.
22. Leiguarda RC, Merello M, Nouzeilles MI, Balej J, Rivero A, Nogués M. Limb-
kinetic apraxia in corticobasal degeneration: clinical and kinematic features.
Mov Disord. (2003) 18:49–59. doi: 10.1002/mds.10303
23. Leiguarda R, Merello M, Balej J, Starkstein S, Nogues M, Marsden CD.
Disruption of spatial organization and interjoint coordination in Parkinson’s
disease, progressive supranuclear palsy, and multiple system atrophy. Mov
Disord. (2000) 15:627–40. doi: 10.1002/1531-8257(200007)15:4<627::AID-
MDS1006>3.0.CO;2-5
24. Nitrini R, Mathias SC, Caramelli P, Carrilho PE, Lefèvre BH, Porto CS, et al.
Evaluation of 100 patients with dementia in São Paulo, Brazil: correlation
with socioeconomic status and education.Alzheimer Dis Assoc Disord. (1995)
9:146–51. doi: 10.1097/00002093-199509030-00005
25. Delgado AP, Caramelli P, Mansur LL, Jarema G LA. Estudo longitudinal em
caso de Afasia Progressiva Primária. Neuropsychlogia Lat. (1995) 1:9–17.
26. Nitrini R, Rosemberg S. Psychotic symptoms in dementia associated
with motor neuron disease: A pathophysiological hypothesis. J
Neuropsychiatry Clin Neurosci. (1998) 10:456–8. doi: 10.1176/jnp.10.
4.456
27. Caixeta L, Nitrini R. Subtipos clínicos da demêcia frontotemporal = clinical
subtypes of frontotemporal dementia.Arq Neuropsiquiatr. (2001) 59:577–81.
doi: 10.1590/S0004-282X2001000400017
28. Allegri RF, Harris P, Feldman M, Taragano F, Paz J. [Differential cognitive
profiles of fronto-temporal dementia and Alzheimer’s disease]. Rev Neurol.
(1998) 27:463–6.
29. De Brito-Marques PR, De Mello RV. Amyotrophic lateral
sclerosis with dementia: Case report. Arq Neuropsiquiatr. (1999)
57:277–83. doi: 10.1590/S0004-282X1999000200018
30. Gustafson L. Clinical classification of dementia conditions. Acta Neurol
Scand. (1992) 85:16–20.
31. Doval Ós, Gaviria M. Demencia frontemporal una redimensión de la
enfermedad de Pick - frontotemporal dementia. Rev Colomb Psiquiatr.
(2000) 29:127–54. Available online at: http://www.scielo.org.co/scielo.php?
script=sci_arttext&pid=S0034-74502000000200005&lng=en&nrm=iso
32. Spatt J. Arnold Pick’s concept of dementia. Cortex. (2003) 39:525–
31. doi: 10.1016/S0010-9452(08)70262-4
33. Cummings J, Benson F. Dementia-A Clinical Approach. 2nd ed. Wiley.
Boston: Butterworth Heinemann (1992). p. 928.
34. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal
assessment battery at bedside. Neurology. (2000) 55:1621–
6. doi: 10.1212/WNL.55.11.1621
35. Ibanez A, Flichtentrei D, Hesse E, Dottori M, Tomio A, Slachevsky A, et al.
The power of knowledge about dementia in Latin America across health
professionals working on aging. Alzheimer’s Dement Diagn Assess Dis Monit.
(2020) 12:e12117. doi: 10.1002/dad2.12117
36. Custodio N, Becerra-Becerra Y, Cruzado L, Castro-Suárez S, Montesinos
R, Bardales Y, et al. Knowledge level of fronto-temporal dementia
in a sample of physicians that regularly assessing patients with
dementia in Lima-Peru. Rev Chil Neuropsiquiatr. (2018) 56:77–88.
doi: 10.4067/s0717-92272018000200077
37. Caixeta L, Dozzi Brucki SM. Subdiagnostic frontotemporal dementia. Arq
Neuropsiquiatr. (2005) 63:186. doi: 10.1590/S0004-282X2005000100036
38. Gleichgerrcht E, Flichtentrei D, Manes F. How much do physicians in Latin
America know about behavioral variant frontotemporal dementia? J Mol
Neurosci. (2011) 45:609–17. doi: 10.1007/s12031-011-9556-9
39. Custodio N, Herrera-Perez E, Lira D, Montesinos R, Bendezu L.
Prevalence of frontotemporal dementia in community-based studies in
Latin America: a systematic review. Dement Neuropsychol. (2013) 7:27–
32. doi: 10.1590/S1980-57642013DN70100005
40. Maestre GE, Pino-Ramírez G, Molero AE, Silva ER, Zambrano R, Falque
L, et al. The Maracaibo aging study: population and methodological issues.
Neuroepidemiology. (2002) 21:194–201. doi: 10.1159/000059524
41. Prevalencia de Demencia en Una Población Urbana de Lima-Perú: Estudio
Puerta a Puerta Available online at: http://www.scielo.org.pe/scielo.php?
pid=S1025-55832008000400003&script=sci_arttext (accessed April 9, 2021).
42. Lopes MA. Estudo Epidemiológico de Prevalência de
Demência em Ribeirão Preto. (2006). Available online at:
http://www.teses.usp.br/teses/disponiveis/5/5142/tde-18042007-110300/
(accessed April 9, 2021).
43. Herrera E, Caramelli P, Silveira ASB, Nitrini R. Epidemiologic survey of
dementia in a community-dwelling Brazilian population. Alzheimer Dis
Assoc Disord. (2002) 16:103–8. doi: 10.1097/00002093-200204000-00007
44. Molero AE, Pino-Ramírez G, Maestre GE. High prevalence of
dementia in a caribbean population. Neuroepidemiology. (2007)
29:107–12. doi: 10.1159/000109824
45. Llibre Guerra JJ, Rodriguez Salgado AM, Peñalver AI, Diaz Marante
JP. The diagnostic challenge of psychiatric symptoms in patients with
dementia in the cuban population. Alzheimer’s Dement. (2017) 13:P1328.
doi: 10.1016/j.jalz.2017.06.2038
46. Silva DW, Damasceno BP. Dementia in patients of UNICAMP
University Hospital. Arq Neuropsiquiatr. (2002) 60:996–9.
doi: 10.1590/s0004-282x2002000600020
47. Cano CA, Ramírez RA. Avances nosológicos de las demencias.
Caracterización de los pacientes con demencia frontotemporal. MedUNAB.
Frontiers in Neurology | www.frontiersin.org 9 September 2021 | Volume 12 | Article 710332
Llibre-Guerra et al. Frontotemporal Dementia in Latin America
(2004) 7:84–8. Recuperado a partir de https://revistas.unab.edu.co/index.
php/medunab/article/view/225
48. Moreno LP, Matallana DL, Cano CA. Actuales retos diagnósticos a partir
de un análisis de características Sociodemográficas de 2453 pacientes de
una Clínica de Memoria y Cognición. Acta Neurol Colomb. (2015) 31:27–
38. doi: 10.22379/242240225
49. Donoso SA, Figueroa VC, Gómez RR, Behrens PMI. Demencia
frontotemporal: experiencia clínica. Rev Med Chil. (2009) 137:900–5.
doi: 10.4067/s0034-98872009000700006
50. Guimarães HC, Espindola T de C. Variante comportamental da
demência frontotemporal de início muito tardio. Dement Neuropsychol.
(2013) 7:136–9. doi: 10.1590/S1980-57642013DN70100020
51. Gambogi LB, Guimarães HC, De Souza LC, Caramelli P. Long-term severe
mental disorders preceding behavioral variant frontotemporal dementia:
frequency and clinical correlates in an outpatient sample. J Alzheimer’s Dis.
(2018) 66:1577–85. doi: 10.3233/JAD-180528
52. Gleichgerrcht E, Ibáñez A, Roca M, Torralva T, Manes F. Decision-making
cognition in neurodegenerative diseases. Nat Rev Neurol. (2010) 6:611–23.
doi: 10.1038/nrneurol.2010.148
53. Gleichgerrcht E, Torralva T, Roca M, Pose M, Manes F. The role of social
cognition in moral judgment in frontotemporal dementia. Soc Neurosci.
(2011) 6:113–22. doi: 10.1080/17470919.2010.506751
54. Baez S, Pinasco C, Roca M, Ferrari J, Couto B, García-
Cordero I, et al. Brain structural correlates of executive and
social cognition profiles in behavioral variant frontotemporal
dementia and elderly bipolar disorder. Neuropsychologia. (2019)
126:159–69. doi: 10.1016/j.neuropsychologia.2017.02.012
55. Melloni M, Lopez V, Ibanez A. Empathy and contextual
social cognition. Cogn Affect Behav Neurosci. (2014) 14:407–
25. doi: 10.3758/s13415-013-0205-3
56. Melloni M, Billeke P, Baez S, Hesse E, De La Fuente L, Forno G, et al.
Your perspective and my benefit: multiple lesion models of self-other
integration strategies during social bargaining. Brain. (2016) 139:3022–
40. doi: 10.1093/brain/aww231
57. Sedeño L, Couto B, García-Cordero I, Melloni M, Baez S, Sepúlveda
JPM, et al. Brain network organization and social executive performance
in frontotemporal dementia. J Int Neuropsychol Soc. (2016) 22:250–
62. doi: 10.1017/S1355617715000703
58. Sedeño L, Piguet O, Abrevaya S, Desmaras H, García-Cordero I, Baez
S, et al. Tackling variability: a multicenter study to provide a gold-
standard network approach for frontotemporal dementia.Hum Brain Mapp.
(2017) 38:3804–22. doi: 10.1016/j.neubiorev.2019.02.020
59. Garcia-Cordero I, Sedeño L, BabinoA, DottoriM,MelloniM,Martorell Caro
M, et al. Explicit and implicit monitoring in neurodegeneration and stroke.
Sci Rep. (2019) 9:11. doi: 10.1038/s41598-019-50599-x
60. Gleichgerrcht E, Torralva T, Roca M, Szenkman D, Ibanez A, Richly P, et al.
Decision making cognition in primary progressive aphasia. In: Behavioural
Neurology. Hindawi Limited. (2012) p. 45–52.
61. Manes F, Torralva T, Ibáñez A, Roca M, Bekinschtein T, Gleichgerrcht
E. Decision-making in frontotemporal dementia: clinical, theoretical
and legal implications. Dement Geriatr Cogn Disord. (2011) 32:11–
7. doi: 10.1159/000329912
62. Ibanez A, Manes F. Contextual social cognition and the behavioral variant of
frontotemporal dementia. Neurology. (2012) 78:1354–62.
63. Couto B, Manes F, Montañés P, Matallana D, Reyes P, Velasquez M,
et al. Structural neuroimaging of social cognition in progressive non-fluent
aphasia and behavioral variant of frontotemporal dementia. Front Hum
Neurosci. (2013) 7:467. doi: 10.3389/fnhum.2013.00467
64. Fittipaldi S, Ibanez A, Baez S, Manes F, Sedeno L, Garcia AM. More than
words: Social cognition across variants of primary progressive aphasia.
Neurosci Biobehav. Rev. (2019) 100:263–84.
65. Baez S, Couto B, Torralva T, Sposato LA, Huepe D, Montañes P, et al.
Comparing moral judgments of patients with frontotemporal dementia and
frontal stroke. JAMA Neurol. (2014) 71:1172–6.
66. Baez S, Manes F, Huepe D, Torralva T, Fiorentino N, Richter F, et al. Primary
empathy deficits in frontotemporal dementia. Front Aging Neurosci. (2014)
6:262. doi: 10.3389/fnagi.2014.00262
67. Baez S, Morales JP, Slachevsky A, Torralva T, Matus C, Manes F,
et al. Orbitofrontal and limbic signatures of empathic concern and
intentional harm in the behavioral variant frontotemporal dementia. Cortex.
(2016) 75:20–32.
68. Serrano C, Allegri RF, Martelli M, Taragano F, Rinalli P. Visual art, creativity
and dementia. Vertex. (2005) 16:418–29.
69. Torralva T, Kipps CM, Hodges JR, Clark L, Bekinschtein T, Roca M, et al.
The relationship between affective decision-making and theory of mind in
the frontal variant of fronto-temporal dementia. Neuropsychologia. (2007)
45:342–9. doi: 10.1016/j.neuropsychologia.2006.05.031
70. Torralva T, Sposato LA, Riccio PM, Gleichgerrcht E, Roca M, Toledo
JB, et al. Role of brain infarcts in behavioral variant frontotemporal
dementia. Clinicopathological characterization in the National Alzheimer’s
Coordinating Center database. Neurobiol Aging. (2015) 36:2861–8.
doi: 10.1016/j.neurobiolaging.2015.06.026
71. Bachli MB, Sedeño L, Ochab JK, Piguet O, Kumfor F, Reyes P, et al.
Evaluating the reliability of neurocognitive biomarkers of neurodegenerative
diseases across countries: a machine learning approach. Neuroimage. (2020)
208:116456. doi: 10.1016/j.neuroimage.2019.116456
72. Donnelly-Kehoe PA, Pascariello GO, García AM, Hodges JR, Miller B,
Rosen H, et al. Robust automated computational approach for classifying
frontotemporal neurodegeneration: multimodal/multicenter neuroimaging.
Alzheimer’s Dement Diagnosis, Assess Dis Monit. (2019) 11:588–98.
doi: 10.1016/j.dadm.2019.06.002
73. Taragano FE, Allegri RF, Heisecke SL, Martelli MI, Feldman ML,
Sánchez V, et al. Risk of conversion to dementia in a mild behavioral
impairment group compared to a psychiatric group and to a mild cognitive
impairment group. J Alzheimer’s Dis. (2018) 62:227–38. doi: 10.3233/JAD-17
0632
74. Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM,
Loñ L, et al. Mild behavioral impairment and risk of dementia: a
prospective cohort study of 358 patients. J Clin Psychiatry. (2009) 70:584–
92. doi: 10.4088/JCP.08m04181
75. Taragano FE, Allegri RF, Lyketsos C. Mild behavioral impairment: a
prodromal stage of dementia. Dement Neuropsychol. (2008) 2:256–60.
doi: 10.1590/s1980-57642009dn20400004
76. Tabernero ME, Politis DG. Basic and complex emotion recognition in
the beheavioural variant of frontotemporal dementia. Neurol Argentina.
(2013) 5:57–65. doi: 10.1016/j.neuarg.2012.12.004
77. Tabernero ME, Rubinstein WY, Cossini FC, Politis DG. Facial
recognition of basic emotions in behavioral variant Frontotemporal
Dementia and in Alzheimer’s disease. Neurol Argentina. (2016) 8:8–16.
doi: 10.1016/j.neuarg.2015.06.001
78. Torralva T, Roca M, Gleichgerrcht E, Bonifacio A, Raimondi C,
Manes F. Validation of the Spanish Version of the Addenbrooke’s
Cognitive Examination-Revised (ACE-R). Neurologia. (2011) 26:351–
6. doi: 10.1016/j.nrl.2010.10.013
79. Custodio N, Lira D, Montesinos R, Gleichgerrcht E, Manes F. [Usefulness
of the Addenbrooke’s cognitive examination (Spanish version) in Peruvian
patients with Alzheimer’s disease and Frontotemporal Dementia]. Vertex.
(2012) 23:165–72.
80. Bento Lima da Silva T, Bahia V, Amore Cecchini M, Cassimiro L, Amaral
Carvalho V, Cerqueira Guimarães H, et al. Cross-cultural adaptation and
validity of the brazilian version of the clinical staging scale and disease
progression in frontotemporal dementia. J Neurochem. (2016) 138:301.
doi: 10.1111/jnc.13692
81. Branco LMT, Zanao T, De Rezende TJ, Casseb RF, Balthazar MF, Woolley
SC, et al. Transcultural validation of the ALS-CBS cognitive section for
the Brazilian population. Amyotroph Lateral Scler Front Degener. (2017)
18:60–7. doi: 10.1080/21678421.2016.1211147
82. Bruno D, Slachevsky A, Fiorentino N, Rueda DS, Bruno G, Tagle
AR, et al. Argentinian/Chilean validation of the Spanish-language
version of Addenbrooke’s Cognitive Examination III for diagnosing
dementia. Neurologia. (2017) 35:82–8. doi: 10.1016/j.nrl.2017.
06.004
83. Jory JI, Bruna AA, Muñoz-Neira C, Chonchol AS. Chilean version
of the INECO Frontal Screening (IFS-Ch): psychometric properties
Frontiers in Neurology | www.frontiersin.org 10 September 2021 | Volume 12 | Article 710332
Llibre-Guerra et al. Frontotemporal Dementia in Latin America
and diagnostic accuracy. Dement e Neuropsychol. (2013) 7:40–7.
doi: 10.1590/s1980-57642013dn70100007
84. Carvalho VA, Caramelli P. Brazilian adaptation of the
Addenbrooke’s Cognitive Examination-Revised (ACE-R). Dement
Neuropsychol. (2007) 1:212–6. doi: 10.1590/s1980-57642008dn1020
0015
85. Belfort T, Bramham J, Simões Neto JP, Sousa MFB De, dos Santos RL,
Nogueira MML, et al. Adaptação transcultural do questionário social e
emocional na demência para a população brasileira. São Paulo Med J.
(2015) 133:358–66. doi: 10.1590/1516-3180.2014.00180501
86. Torralva T, Roca M, Gleichgerrcht E, Bekinschtein T, Manes F. A
neuropsychological battery to detect specific executive and social cognitive
impairments in early frontotemporal dementia. Brain. (2009) 132:1299–
309. doi: 10.1093/brain/awp041
87. Custodio N, Herrera-Perez E, Lira D, Roca M, Manes F, Báez S,
et al. Evaluation of the INECO frontal screening and the frontal
assessment battery in peruvian patients with alzheimer’s disease and
behavioral variant frontotemporal dementia. eNeurologicalSci. (2016) 5:25–
9. doi: 10.1016/j.ensci.2016.11.001
88. Bahia VS, Cecchini MA, Cassimiro L, Viana R, Lima-Silva TB, De Souza LC,
et al. The accuracy of INECO frontal screening in the diagnosis of executive
dysfunction in frontotemporal dementia and Alzheimer disease. Alzheimer
Dis Assoc Disord. (2018) 32:314–9. doi: 10.1097/WAD.0000000000000255
89. Sedeno L, Piguet O, Abrevaya S, Desmaras H, Garcia-Cordero I, Baez S,
et al. Tackling variability: a multicenter study to provide a gold-standard
network approach for frontotemporal dementia. Hum Brain Mapp. (2017)
38:3804–22. doi: 10.1002/hbm.23627
90. Baez S, Kanske P, Matallana D, Montañes P, Reyes P, Slachevsky A, et al.
Integration of intention and outcome for moral judgment in frontotemporal
dementia: brain structural signatures. Neurodegener Dis. (2016) 16:206–17.
doi: 10.1159/000441918
91. Nitrini R, Takada LT, Nascimento CF, Grinberg LT, Chadi G, Bahia
VS. P2-026: Novel GRN mutations in two brazilian kindreds: clinical,
neuroimaging, and neuropathological characteristics. Alzheimer’s Dement.
(2015) 11:P491. doi: 10.1016/j.jalz.2015.06.562
92. Takada LT. The genetics of monogenic frontotemporal dementia. Dement
Neuropsychol. (2015) 9:219-29. doi: 10.1590/1980-57642015DN93000003
93. Gargiulo Monachelli G, LeBlond C, Bettini M, Vazquez-Varela J, Figueredo
MA, Lautre A, et al. Frequency of the expanded hexanucleotide G4C2 repeat
in the C9ORF72 gene and clinical features of patients presenting to ALS
referral centers in Buenos Aires, Argentina: preliminary results. (P2.050).
Neurology. (2015). 84:P2.050.
94. Jin SC, Pastor P, Cooper B, Cervantes S, Benitez BA, Razquin C, et al.
Pooled-DNA sequencing identifies novel causative variants in PSEN1,
GRN and MAPT in a clinical early-onset and familial Alzheimer’s disease
Ibero-American cohort. Alzheimer’s Res Ther. (2012) 4:34. doi: 10.1186/alz
rt137
95. Ryan M, Zaldívar Vaillant T, McLaughlin RL, Doherty MA, Rooney J,
Heverin M, et al. Comparison of the clinical and genetic features of
amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-
based populations. J Neurol Neurosurg Psychiatry. (2019) 90:659–65.
doi: 10.1136/jnnp-2018-319838
96. Miranda C M, Bustamante C ML, Herrera C L. Expansión anormal
de hexanucleótido en gen C9orf72 en una familia con demencia
frontotemporal y cuadros asociados TT - abnormal expansion of C9orf72
gene in familial frontotemporal dementia. Rev Med Chil. (2017) 145:896–
900. doi: 10.4067/s0034-98872017000700896
97. Momeni P, Detucci K, Straub RE, Weinberger DR, Davies P, Grafman
J, et al. Progranulin (GRN) in two siblings of a Latino family
and in other patients with schizophrenia. Neurocase. (2010). 16:273–
9. doi: 10.1080/13554790903456209
98. Cintra VP, Bonadia LC, Andrade HMT, de Albuquerque M, Eusébio
MF, de Oliveira DS, et al. The frequency of the C9orf72 expansion
in a Brazilian population. Neurobiol Aging. (2018) 66:179.e1-e4.
doi: 10.1016/j.neurobiolaging.2018.01.007
99. Takada LT, Pimentel ML V., DeJesus-Hernandez M, Fong JC, Yokoyama JS,
Karydas A, et al. Frontotemporal dementia in a Brazilian kindred with the
C9orf72 mutation. Arch Neurol. (2012) 69:1149–53.
100. Fernández Suarez M, Surace E, Harris P, Tapajoz F, Sevlever G,
Allegri R, et al. C9ORF72 G4C2-repeat expansion and frontotemporal
dementia first reported case in Argentina. Neurocase. (2016) 22:281–
4. doi: 10.1080/13554794.2016.1186700
101. Itzcovich T, Xi Z, Martinetto H, Chrem-Méndez P, Russo MJ, de
Ambrosi B, et al. Analysis of C9orf72 in patients with frontotemporal
dementia and amyotrophic lateral sclerosis fromArgentina.Neurobiol Aging.
(2016) 40:192.e13-e15. doi: 10.1016/j.neurobiolaging.2016.02.001
102. Niikado M, Calandri IL, Kennedy MB, Itzcovich T, Martinetto H,
Vazquez S, et al. P4-105: progranulin C.709-1ga variant in an Argentine
family with behavioral variant frontotemporal dementia and semantic
primary progressive aphasia. Alzheimer’s Dement. (2019) 15:P1315.
doi: 10.1016/j.jalz.2019.06.3766
103. Takada LT, Bahia VS, Guimarães HC, Costa TVMM, Vale TC, Rodriguez
RD, et al. GRN and MAPT mutations in 2 frontotemporal dementia
research centers in Brazil. Alzheimer Dis Assoc Disord. (2016) 30:310–
7. doi: 10.1097/WAD.0000000000000153
104. Gatto EM, Allegri RF, Da Prat G, Chrem Mendez P, Hanna DS,
Dorschner MO, et al. Intrafamilial variable phenotype including corticobasal
syndrome in a family with p.P301L mutation in the MAPT gene:
first report in South America. Neurobiol Aging. (2017) 53:195.e11-17.
doi: 10.1016/j.neurobiolaging.2017.02.002
105. Fanganiello RD, Kimonis VE, Côrte CC, Nitrini R, Passos-Bueno MR.
A Brazilian family with hereditary inclusion body myopathy associated
with Paget disease of bone and frontotemporal dementia. Brazilian
J Med Biol Res. (2011) 44:374–80. doi: 10.1590/S0100-879X20110075
00028
106. Lee JH, Kahn A, Cheng R, Reitz C, Vardarajan B, Lantigua R,
et al. Disease-related mutations among caribbean hispanics with familial
dementia. Mol Genet Genomic Med. (2014) 2:430–7. doi: 10.1002/m
gg3.85
107. Nascimento C, Suemoto CK, Rodriguez RD, Alho ATDL, Leite RP, Farfel
JM, et al. Higher prevalence of TDP-43 proteinopathy in cognitively normal
asians: a clinicopathological study on a multiethnic sample. Brain Pathol.
(2016) 26:177–85. doi: 10.1111/bpa.12296
108. Niikado M, Chrem-Méndez P, Itzcovich T, Barbieri-Kennedy M,
Calandri I, Martinetto H, et al. Evaluation of cerebrospinal fluid
neurofilament light chain as a routine biomarker in a memory clinic.
J Gerontol A Biol Sci Med Sci. (2019) 74:442–5. doi: 10.1093/gerona/g
ly179
109. Fraga VG, Magalhães CA, Loures C de MG, de Souza LC, Guimarães
HC, Zauli DAG, et al. Inflammatory and pro-resolving mediators in
frontotemporal dementia and Alzheimer’s disease. Neuroscience. (2019)
421:123–35. doi: 10.1016/j.neuroscience.2019.09.008
110. Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, et al.
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl
Med Mol Imaging. (2008) 35:100–6. doi: 10.1007/s00259-007-0523-1
111. Nascimento C, Kyunghee Kim H, Cristina De Oliveira K, Moretto AC,
Brentani HP, Andreazza A, et al. Increased levels of TDP-43 protein
in postmortem brain tissue of bipolar disorder subjects. Bipolar Disord.
(2017) 19:126. doi: 10.1111/bdi.12480/abstract
112. De Brito-Marques PR, De Mello RV, Montenegro L. Classic Pick’s disease
type with ubiquitin-positive and tau-negative inclusions: case report.
Arq Neuropsiquiatr. (2001) 59:128–33. doi: 10.1590/S0004-282X20010001
00028
113. Senaha MLH, Caramelli P, Brucki SMD, Smid J, Takada LT, Porto
CS, et al. Primary progressive aphasia: classification of variants in
100 consecutive Brazilian cases. Dement Neuropsychol. (2013) 7:110–
21. doi: 10.1590/S1980-57642013DN70100017
114. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez MF,
Cappa SF, et al. Classification of primary progressive aphasia and its
variants. Neurology. (2011) 76:1006–14. doi: 10.1212/WNL.0b013e31821
103e6
115. Campanha AC, Machado TH, Carvalho VA, Dos Santos EL, Carthery-
Goulart MT, Guimarães HC, et al. Primary progressive aphasia:
Demographic, clinical, and imaging correlates in patients classified
according to the 2011 diagnostic criteria. Alzheimer’s Dement. (2015)
11:P824. doi: 10.1016/j.jalz.2015.06.1827
Frontiers in Neurology | www.frontiersin.org 11 September 2021 | Volume 12 | Article 710332
Llibre-Guerra et al. Frontotemporal Dementia in Latin America
116. Marin S, Bertolucci PH, Marin LF, de Oliveira FF, Wajman JR, Bahia VS, et
al. Swallowing in primary progressive aphasia. NeuroRehabilitation. (2016)
38:85–92. doi: 10.3233/NRE-151299
117. Caixeta L, Caixeta M. Primary progressive aphasia beginning
with a psychiatric disorder. Clinics. (2011) 66:1505–
7. doi: 10.1590/S1807-59322011000800035
118. Hosogi Senaha ML, Caramelli P, Nitrini R, Charchat-Fichman H, Weekes
BS. Semantic dementia without surface dyslexia in Portuguese. Brain Lang.
(2006) 99:42–3. doi: 10.1016/j.bandl.2006.06.031
119. WilsonMA,Martínez-CuitioM. Semantic dementia without surface dyslexia
in Spanish: Unimpaired reading with impaired semantics. Behav Neurol.
(2012) 25:273–84. doi: 10.1155/2012/258685
120. de Brito-Marques, PR, Vieira-Mello RJ, Montenegro L, de Fátima Vasco
Aragão M. Clinicopathologic analysis of progressive non-fluent aphasia and
corticobasal degeneration: Case report and review. Dement Neuropsychol.
(2011) 5:135–41. doi: 10.1590/S1980-57642011DN05020013
121. Andrade-Calderón P, Salvador-Cruz J, Sosa-Ortiz AL. Impacto positivo da
terapia da linguagem em afasia progressiva não fluente. Acta Colomb Psicol.
(2015) 18:101–14.
122. Senaha MLH, Brucki SMD, Nitrini R. Reabilitação na demência semântica:
Estudo da eficácia da reaquisição lexical em três pacientes. Dement
Neuropsychol. (2010) 4:306–12. doi: 10.1590/S1980-57642010DN40400009
123. Machado TH, Campanha AC, Caramelli P, Carthery-Goulart MT. Short-
term rehabilitation for linguistic impairments in semantic and agrammatic
variants of primary progressive aphasia: a case series. Alzheimer’s Dement.
(2015) 11:P469. doi: 10.1016/j.jalz.2015.06.497
124. Beber BC, Berbert MCB, Grawer RS, Cardoso MC de AF. Estratégias
de controle de ritmo e taxa de fala para a apraxia de fala na afasia
progressiva primária não-fluente. Dement e Neuropsychol. (2018) 12:80–4.
doi: 10.1590/1980-57642018dn12-010012
125. Bak TH. Motor neuron disease and frontotemporal dementia: one,
two, or three diseases. Ann Indian Acad Neurol. (2010) 13:S81–
8. doi: 10.4103/0972-2327.74250
126. Nitrini R, Rosemberg S. Psychotic symptoms in dementia associated with
motor neuron disease. J Neuropsychiatry Clin Neurosci. (1998) 10:456–8.
127. Pavez RA, Saá BN. Demencia frontotemporal y esclerosis lateral amiotrófica:
presentación de un caso clínico TT - Frontotemporal dementia and
amyotrophic lateral sclerosis: a case report. Rev Chil Neuropsiquiatr. (2015)
53:286–93. doi: 10.4067/S0717-92272015000400009
128. Guedes ÁCB, Santin R, Costa ASR, Reiter KC, Hilbig A, Fernandez LL.
Distinct phospho-TDP-43 brain distribution in two cases of FTD, one
associated with ALS. Dement e Neuropsychol. (2017) 11:249–54.
129. Segura-Chávez D, Torres-Ramírez L, Vélez-Rojas M, Flores-Mendoza
M. Signo de la copa de vino: a propósito de un caso con esclerosis
lateral primaria y demencia frontotemporal. Rev Neuropsiquiatr. (2019)
82:84. doi: 10.20453/rnp.v82i1.3486
130. Branco LMT, Zanao TA, de Rezende TJR, et al. Behavioral
manifestations in a Brazilian non-demented C9orf72-negative
ALS population. Amyotroph Lateral Scler Front Degener. (2020)
21:100–6. doi: 10.1080/21678421.2019.1704014
131. Branco LMT, de Rezende TJR, Roversi C de O, et al. Brain
signature of mild stages of cognitive and behavioral impairment in
amyotrophic lateral sclerosis. Psychiatry Res Neuroimaging. (2018)
272:58–64. doi: 10.1016/j.pscychresns.2017.11.010
132. Turon-Sans J, Gascon-Bayarri J, Reñé R, et al. Cognitive impairment
in ALS patients and validation of the Spanish version of the ALS-
CBS test. Amyotroph Lateral Scler Front Degener. (2016) 17:221–
7. doi: 10.3109/21678421.2015.1125500
133. Pinto-Grau M, Burke T, Lonergan K, et al. Screening for cognitive
dysfunction in ALS: validation of the Edinburgh Cognitive and
Behavioural ALS Screen (ECAS) using age and education adjusted
normative data. Amyotroph Lateral Scler Front Degener. (2017)
18:99–106. doi: 10.1080/21678421.2016.1249887
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Llibre-Guerra, Behrens, Hosogi, Montero, Torralva, Custodio,
Longoria-Ibarrola, Giraldo-Chica, Aguillón, Hardi, Maestre, Contreras, Doldan,
Duque-Peñailillo, Hesse, Roman, Santana-Trinidad, Schenk, Ocampo-Barba,
López-Contreras and Nitrini. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 12 September 2021 | Volume 12 | Article 710332
